Ribonova
2 known investors
Ribonova is a biopharmaceutical company discovering and developing novel small-molecule medicines for patients with serious rare diseases. Its lead candidate, R007, is a Phase-2-ready treatment for inherited mitochondrial disease.
BiotechMedical Devices
Investors · 2
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $299.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $973.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $1.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2015 | $177.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Ribonova do?
- Ribonova is a biopharmaceutical company discovering and developing novel small-molecule medicines for patients with serious rare diseases. Its lead candidate, R007, is a Phase-2-ready treatment for inherited mitochondrial disease.
- Who are Ribonova's investors?
- Ribonova's investors include BioAdvance, Militia Hill Ventures.